Rowan E Chapman, a director at Natera, Inc. (NASDAQ:NTRA), sold company stock totaling $37,100 on July 15, 2026.
The transaction involved the sale of 135 shares of Natera common stock at a price of $274.82 per share. The sale comes as the stock trades near its 52-week high of $288.04, following a remarkable 95% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Following this sale, Mr. Chapman directly holds 4,663 shares of Natera common stock. The sale was executed under a Rule 10b5-1 trading plan, which Mr. Chapman adopted on December 12, 2025. For deeper insights into Natera’s valuation and performance metrics, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.
In other recent news, Natera Inc. announced that its Signatera test received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). This certification encompasses the Signatera platform, including its assay, specimen collection kit, and associated software. Additionally, Natera published data in JAMA Oncology showing that its molecular residual disease (MRD) test predicts chemotherapy benefits in patients with resected colorectal liver metastases. The study involved 298 patients and was presented at the European Society for Medical Oncology Gastrointestinal Congress.
Natera also partnered with Aveta Biomics for a Phase 3 clinical trial evaluating APG-157 in patients with head and neck squamous cell carcinoma. This trial will utilize Natera’s Signatera testing to assess treatment response and molecular residual disease. Furthermore, Bernstein SocGen Group resumed coverage on Natera with an outperform rating, citing the company’s path to increased volumes and reimbursement in MRD testing. Lastly, Natera received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for its Signatera test, marking it as the first PMDA-approved MRD test in Japan for colorectal cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.